Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation
2024

Rapid Changes in Metastases of G3 Neuroendocrine Tumors

Sample size: 40 publication 10 minutes Evidence: moderate

Author Information

Author(s): Kasajima Atsuko, Pfarr Nicole, Mayr Eva-Maria, Ura Ayako, Moser Elisa, von Werder Alexander, Agaimy Abbas, Pavel Marianne, Klöppel Günter

Primary Institution: Technical University Munich, TUM School of Medicine and Health, Munich, Germany

Hypothesis

What are the morphomolecular features and progression characteristics of metastasized G3 neuroendocrine tumors under systemic treatment?

Conclusion

The study found that rapid progression in patients with metastasized G3 neuroendocrine tumors is associated with significant increases in Ki67 and the presence of TP53 mutations.

Supporting Evidence

  • Nine out of 40 G3 neuroendocrine tumors exhibited NEC-like features.
  • All NEC-like tumors showed a significantly higher Ki67 increase compared to non-NEC-like G3NETs.
  • All NEC-like G3NETs had TP53 mutations, indicating a potential driver of rapid tumor growth.
  • Patients with NEC-like G3NETs had a longer interval time between examinations compared to those without.
  • Patients with NEC-like features received more systemic treatment regimens prior to transformation.

Takeaway

Doctors studied 40 patients with a type of tumor called G3 neuroendocrine tumors and found that some of them changed quickly and had a specific mutation that made them grow faster.

Methodology

The study reviewed clinical and histological findings in 40 patients with metastasized G3 neuroendocrine tumors, examining tissue samples taken at least twice over a median interval of 27 months.

Potential Biases

Potential biases may arise from the retrospective nature of the study and selection of patients.

Limitations

The study is limited by its retrospective design and the small sample size of patients with NEC-like features.

Participant Demographics

The median age of participants was 58 years, with an equal distribution of male and female patients.

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s12022-024-09827-y

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication